Literature DB >> 20588027

Characteristics of symptomatic reflux episodes in patients with non-erosive reflux disease who have a positive symptom index on proton pump inhibitor therapy.

Katsuhiko Iwakiri1, Hirohito Sano, Yuriko Tanaka, Noriyuki Kawami, Mariko Umezawa, Seiji Futagami, Yoshio Hoshihara, Tsutomu Nomura, Masao Miyashita, Choitsu Sakamoto.   

Abstract

BACKGROUND AND AIM: The reason that some reflux episodes evoke symptoms is poorly understood, therefore the aim of this study is to assess the determinants of reflux perception in patients with non-erosive reflux disease (NERD) on proton pump inhibitor (PPI) therapy.
METHODS: Ten NERD patients with persistent symptoms, despite double-dose PPI therapy, were included in this study. All patients had a positive symptom index (SI), which was determined by ambulatory 24-hour combined impedance-pH monitoring. Reflux episodes were identified and classified as acid, weakly acidic or weakly alkaline reflux and were considered symptomatic if patients recorded a symptom within 5 min after a reflux episode.
RESULTS: A total of 954 liquid reflux episodes were detected, including 135 (14.2%) acid, 782 (82.0%) weakly acidic, and 37 (3.9%) weakly alkaline. Overall, 59 (6.2%) reflux episodes were symptomatic and the majority (88.1%) of symptomatic reflux episodes were weakly acidic reflux. When reflux episodes were confined to the distal esophagus, there were very few reflux symptoms. Proximal reflux is significantly more likely to be associated with reflux symptoms, irrespective of the acidity of the refluxate or the duration of proximal reflux episodes.
CONCLUSIONS: In NERD patients who have a positive SI on double-dose PPI therapy, the high proximal extent of refluxate is a major factor associated with reflux perception. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20588027     DOI: 10.1159/000309483

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  6 in total

Review 1.  Management of refractory typical GERD symptoms.

Authors:  Emidio Scarpellini; Daphne Ang; Ans Pauwels; Adriano De Santis; Tim Vanuytsel; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-14       Impact factor: 46.802

Review 2.  Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.

Authors:  Katsuhiko Iwakiri; Yoshikazu Kinoshita; Yasuki Habu; Tadayuki Oshima; Noriaki Manabe; Yasuhiro Fujiwara; Akihito Nagahara; Osamu Kawamura; Ryuichi Iwakiri; Soji Ozawa; Kiyoshi Ashida; Shuichi Ohara; Hideyuki Kashiwagi; Kyoichi Adachi; Kazuhide Higuchi; Hiroto Miwa; Kazuma Fujimoto; Motoyasu Kusano; Yoshio Hoshihara; Tatsuyuki Kawano; Ken Haruma; Michio Hongo; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-06-21       Impact factor: 7.527

3.  Characteristics of symptomatic reflux episodes in Japanese proton pump inhibitor-refractory non-erosive reflux disease patients.

Authors:  Kenichiro Nakagawa; Tomoyuki Koike; Katsunori Iijima; Masahiro Saito; Hiroki Kikuchi; Waku Hatta; Nobuyuki Ara; Kaname Uno; Naoki Asano; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

4.  Gastroesophageal reflux symptoms not responding to proton pump inhibitor: GERD, NERD, NARD, esophageal hypersensitivity or dyspepsia?

Authors:  Mohammad Bashashati; Reza A Hejazi; Christopher N Andrews; Martin A Storr
Journal:  Can J Gastroenterol Hepatol       Date:  2014-04-09

5.  Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease.

Authors:  Satoshi Shinozaki; Hiroyuki Osawa; Yoshikazu Hayashi; Yoshimasa Miura; Alan Kawarai Lefor; Hironori Yamamoto
Journal:  Biomed Rep       Date:  2021-02-01

6.  Hypopharyngeal multichannel intraluminal impedance leads to the promising outcome of antireflux surgery in Japanese population with laryngopharyngeal reflux symptoms.

Authors:  Takeshi Suzuki; Yosuke Seki; Yoshitaka Okamoto; Toshitaka Hoppo
Journal:  Surg Endosc       Date:  2017-12-07       Impact factor: 4.584

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.